Hypertrophic obstructive cardiomyopathy: Mechanism of obstruction and response to therapy

Reviews in Cardiovascular Medicine

Volumn 4, Issue 4, 2003, Pages 199-215

  Yoerger, Danita M ^a   Weyman, Arthur E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

blockers; Calcium channel blockers; Hypertrophic cardiomyopathy; Left ventricular outflow tract; Mitral valve; Pacing, atrio ventricular; Septal ablation; Septal myotomy myectomy

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIBENZOLINE; DILTIAZEM; DISOPYRAMIDE; ISOPRENALINE; NIFEDIPINE; PROPRANOLOL; VERAPAMIL;

CLINICAL TRIAL; COMORBIDITY; CONSERVATIVE TREATMENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FATIGUE; HEART ATRIUM PACING; HEART FUNCTION; HEART VENTRICLE PACING; HEART VENTRICLE SEPTUM; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; LUNG ARTERY PRESSURE; MITRAL VALVE; MITRAL VALVE REPLACEMENT; MUSCLE RESECTION; MYOTOMY; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; REVIEW; SIDE EFFECT; SYMPTOMATOLOGY; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; COMBINED MODALITY THERAPY; COMORBIDITY; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HEART VALVE PROSTHESIS; HUMANS; MALE; MITRAL VALVE STENOSIS; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR OUTFLOW OBSTRUCTION;

EID: 0347407808     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999-1006.
2. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:655-670.
3. Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation. 1992;85:1651-1660.
4. Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis. 1985;28:1-83.
5. Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol. 1995;26:1699-1708.
6. Klues HG, Roberts WC, Maron BJ. Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. Circulation. 1991;84;1188-1197.
7. Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87:1570-1579.
8. Tanaka M, Fujiwara H, Onodera T, et al. Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy. Circulation. 1987;75:1130-1139.
9. Goodwin JF. Treatment of the cardiomyopathies. Am J Cardiol. 1973;32:341-351.
10. Goodwin JF. The frontiers of cardiomyopathy. Br Heart J. 1982;48:1-18.
11. Wigle ED. Hypertrophic cardiomyopathy: a 1987 viewpoint. Circulation. 1987;75:311-322.
12. Maron BJ, Bonow RO, Cannon RO 3rd, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med. 1987;316:780-789.
13. Maron BJ, Bonow RO, Cannon RO 3rd, et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med. 1987;316:844-852.
14. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775-785.
15. Jiang L, Levine RA, King ME, Weyman AE. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J. 1987;113:633-644.
16. Pollick C, Rakowski H, Wigle ED. Muscular subaortic stenosis: the quantitative relationship between systolic anterior motion and the pressure gradient. Circulation. 1984;69:43-49.
17. Qin JX, Shiota T, Lever HM, et al. Impact of left ventricular outflow tract area on systolic outflow velocity in hypertrophic cardiomyopathy: a real-time three-dimensional echocardiographic study. J Am Coll Cardiol. 2002; 39:308-314.
18. Goodwin JF. Clinical pharmacology of hypertrophic obstructive cardiomyopathy. In: Wolstenholme GEW, O'Connor M, eds. CIBA Foundation Symposium on the Cardiomyopathies. Boston: Little Brown and Company; 1964.
19. Qin JX, Shiota T, Lever HM, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous translumininal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001;38:1994-2000.
20. Moro E, ten Cate FJ, Leonard JJ, et al. Genesis of systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy: an anatomical or dynamic event? Eur Heart J. 1987; 8:1312-1321.
21. Borer JS, Bacharach SL, Green MV, et al. Effect of septal myotomy and myectomy on left ventricular systolic function at rest and during exercise in patients with IHSS. Circulation. 1979;60(2 Pt 2):82-87.
22. Sakurai S, Tanaka H, Yoshimura H, et al. Production of systolic anterior motion of the mitral valve in dogs. Circulation. 1985;71:805-812.
23. Harrison DC, Braunwald E, Glick G, et al. Effects of beta adrenergic blockade on the circulation, with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation. 1964;29:84-98.
24. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chains of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 1996;13:63-69.
25. Fananapazir L. Advances in molecular genetics and management of hypertrophic cardiomyopathy [see comments] erratum appears in JAMA 1999;282:2303]. JAMA. 1999;281:1746-1752.
26. Sheikhzadeh A, Eslami B, Stierle U, et al. Midventricular obstruction - a form of hypertrophic obstructive cardiomyopathy - and systolic anterior motion of the mitral valve [erratum appears in Clin Cardiol. 1987;10:A45]. Clin Cardiol. 1986;9:607-613.
27. Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. J Am Coll Cardiol. 1987;9:288-294.
28. Desnos M, Hagege A, Guerot C. Hypertrophic cardiomyopathy: place and limitations of medical therapy [in French]. Arch Mal Coeur Vaiss. 1995;88(4 suppl):573-575.
29. Flamm MD, Harrison DC, Hancock EW. Muscular subaortic stenosis. Prevention of outflow obstruction with propranolol. Circulation. 1968;38:846-858.
30. Cohen LS, Braunwald E. Chronic beta adrenergic receptor blockade in the treatment of idiopathic hypertrophic subaortic stenosis. Prog Cardiovasc Dis. 1968;11:211-221.
31. Chatterjee K. Calcium antagonist agents in hypertrophic cardiomyopathy. Am J Cardiol. 1987;59:146B-152B.
32. Sherrid M, Delia E, Dwyer E. Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1988;62:1085-1088.
33. Brush JE Jr, Eisenhofer G, Garty M, et al. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation. 1989; 79:836-844.
34. Stenson RE, Flamm MD Jr, Harrison DC, Hancock EW. Hypertrophic Subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. Am J Cardiol. 1973;31:763-773.
35. Swanton RH, Brooksby IA, Jenkins BS, Webb-Peploe MM. Hemodynamic studies of beta blockade in hypertrophic obstructive cardiomyopathy. Eur J Cardiol. 1977;5:327-341.
36. Shah PM, Gramiak R, Adelman AG, Wigle ED. Echocardiographic assessment of the effects of surgery and propranolol on the dynamics of outflow obstruction in hypertrophic subaortic stenosis. Circulation. 1972;45:516-521.
37. Saenz de la Calzada C, Ziady GM, Hardarson T, et al. Effect of acute administration of propranolol on ventricular function in hypertrophic obstructive cardiomyopathy measured by non-invasive techniques. Br Heart J. 1976;38:798-803.
38. Edwards RH, Kristinsson A, Warrell DA, Goodwin JF. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Br Heart J. 1970;32:219-225.
39. Hess OM, Grimm J, Krayenbuehl HP. Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness. Eur Heart J. 1983;4(suppl F):47-56.
40. Losse B, Kuhn H, Loogen F, Schulte HD. Exercise performance in hypertrophic cardiomyopathies. Eur Heart J. 1983;4(suppl F):197-208.
41. Bourmayan C, Razavi A, Fournier C, et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. Am Heart J. 1985;109:1311-1316.
42. Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847-851.
43. Cherian G, Brockington IM, Shah P, et al. Beta-adrenergic blockade in patients with hypertrophic obstructive cardiomyopathy. Am Heart J. 1967;73:140-141.
44. Adelman AG, Shah PM, Gramiak R, Wigle ED. Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J. 1970;32:804-811.
45. Adelman AG, Wigle ED, Ranganathan N, et al. The clinical course in muscular subaortic stenosis. A retrospective and prospective study of 60 hemodynamically proved cases. Ann Intern Med. 1972;77:515-525.
46. Epstein SE, Maron BJ. Hypertrophic cardiomyopathy: an overview. Clin Invest Med. 1980;3:185-193.
47. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1999;34:1813-1822.
48. Rosing DR, Kent KM, Borer JS, et al. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation. 1979;60:1201-1207.
49. Bonow RO, Rosing DR, Bacharach SL, et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:787-796.
50. Hanrath P, Mathey DG, Kremer P, et al. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol. 1980;45:1258-1264.
51. Bouhour JB, Potiron M, Chiffoleau S, et al. Medical treatment of hypertrophic myocardiopathy. Comparison of propranolol and verapamil [in French]. Arch Mal Coeur Vaiss. 1987;80:76-82.
52. Kober G, Hopf R, Biamino G, et al. Long-term treatment of hypertrophic cardiomyopathy with verapamil or propranolol in matched pairs of patients: results of a multicenter study. Z Kardiol. 1987;76(suppl 3):113-118.
53. Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437-441.
54. Lorell BH, Paulus WJ, Grossman W, et al. Improved diastolic function and systolic performance in hypertrophic cardiomyopathy after nifedipine. N Engl J Med. 1980;303:801-803.
55. Lorell BH, Paulus WJ, Grossman W, et al. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation. 1982;65:499-507.
56. Betocchi S, Cannon RO 3rd, Watson RM, et al. Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy. Circulation. 1985;72:1001-1007.
57. Nagao M, Yasue H, Omote S, et al. Diltiazem-induced decrease of exercise-elevated pulmonary arterial diastolic pressure in hypertrophic cardiomyopathy patients. Am Heart J. 1981;102:789-790.
58. Tokudome T, Mizushige K, Ueda T, et al. Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol - a case report. Angiology 1999;50:331-335.
59. Millaire A, Goullard L, Decoulx E, et al. Efficiency of disopyramide in hypertrophic cardiomyopathy during stress states. Am J Cardiol. 1992;69:423-424.
60. Kondo I, Mizushige K, Nozaki S, et al. Effect of cibenzoline, a class Ia antiarrhythmic agent, on left ventricular diastolic function in hypertrophic cardiomyopathy. Cardiovasc Drugs Ther. 2001;15:459-465.
61. Popp RL, Harrison DC. Ultrasound in the diagnosis and evaluation of therapy of idiopathic hypertrophic subaortic stenosis. Circulation. 1969;40:905-914.
62. Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79:1052-1060.
63. Maron BJ. Hypertrophic cardiomyopathy. Lancet 1997;350:127-133.
64. Morrow AG, Fogarty TJ, Hannah H 3rd, Braunwald E. Operative treatment in idiopathic hypertrophic subaortic stenosis. Techniques and the results of preoperative and postoperative clinical and hemodynamic assessments. Circulation. 1968;37:589-596.
65. Morrow AG, Reitz BA, Epstein SE, et al. Operative treatment in hypertrophic subaortic stenosis. Techniques and the results of pre- and postoperative assessments in 83 patients. Circulation. 1975;52:88-102.
66. Heric B, Lytle BW, Miller DP, et al. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. J Thorac Cardiovasc Surg. 1995;110:195-206; discussion 206-208.
67. Merrill WH, Friesinger GC, Graham TP Jr, et al. Long-lasting improvement after septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2000;69:1732-1735; discussion 1735-1736.
68. Schulte HD, Borisov K, Gams E, et al. Management of symptomatic hypertrophic obstructive cardiomyopathy - long-term results after surgical therapy. Thorac Cardiovasc Surg. 1999;47:213-218.
69. ten Berg JM, Suttorp MJ, Knaepen PJ, et al. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation. 1994;90:1781-1785.
70. Cohn LH, Trehan H, Collins JJ Jr. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:657-660.
71. Seshadri N, Novaro GM, Lever H, et al. Myectomy site thrombus formation: an underappreciated source of thromboembolism after septal myectomy. J Thorac Cardiovasc Surg. 2002;123:562-564.
72. Nakatani S, Schwammenthal E, Lever HM, et al. New insights into the reduction of mitral valve systolic anterior motion after ventricular septal myectomy in hypertrophic obstructive cardiomyopathy. Am Heart J. 1996;131:294-300.
73. Bigelow WG, Trimble AS, Wigle ED, et al. The treatment of muscular subaortic stenosis. J Thorac Cardiovasc Surg. 1974;68:384-392.
74. Nagata S, Park YD, Ohmori F, et al. Anterolateral papillary muscle motion before and after septal myotomy in hypertrophic obstructive cardiomyopathy [in Japanese]. J Cardiol. 1988;18:363-372.
75. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet. 2000;355:425-426.
76. Cooley DA, Leachman RD, Wukasch DC. Diffuse muscular subaortic stenosis: surgical treatment. Am J Cardiol. 1973;31:1-6.
77. Krajcer Z, Leachman RD, Cooley DA, Coronado R. Septal myotomy-myomectomy versus mitral valve replacement in hypertrophic cardiomyopathy. Ten-year follow-up in 185 patients. Circulation. 1989;80(3 Pt 1):I57-I64.
78. Roberts WC. Operative treatment of hypertrophic obstructive cardiomyopathy. The case against mitral valve replacement. Am J Cardiol. 1973;32:377-381.
79. McIntosh CL, Greenberg GJ, Maron BJ, et al. Clinical and hemodynamic results after mitral valve replacement in patients with obstructive hypertrophic cardiomyopathy. Ann Thorac Surg. 1989;47:236-246.
80. McIntosh CL, Maron BJ, Cannon RO 3rd, Klues HG. Initial results of combined anterior mitral leaflet plication and ventricular septal myotomy-myectomy for relief of left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. Circulation. 1992;86(5 suppl):II60-II67.
81. Kofflard MJ, van Herwerden LA, Waldstein DJ, et al. Initial results of combined anterior mitral leaflet extension and myectomy in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1996;28:197-202.
82. Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation. 1998; 98:2505-2508.
83. Johnson AD, Daily PO. Hypertrophic subaortic stenosis complicated by high degree heart block: successful treatment with an atrial synchronous ventricular pacemaker. Chest. 1975;67:491-494.
84. Borromeo L, Wilson WS. Muscular subaortic stenosis. Changing obstruction with atrioventricular dissociation. Ann Intern Med. 1971; 74:242-244.
85. Duck HJ, Hutschenreiter W, Pankau H, Trenckmann H. Atrial synchronous ventricular stimulation with reduced a.v. delay time as a therapeutic principle in hypertrophic obstructive cardiomyopathy [in German]. Z Gesamte Inn Med. 1984;39:437-447.
86. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet. 1992;339:1318-1323.
87. Rishi F, Hulse JE, Auld DO, et al. Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1997;29:734-740.
88. Fananapazir L, Epstein ND, Curiel RV, et al. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90:2731-2742.
89. Betocchi S, Losi MA, Piscione F, et al. Effects of dual-chamber pacing in hypertrophic cardiomyopathy on left ventricular outflow tract obstruction and on diastolic function. Am J Cardiol. 1996;77:498-502.
90. Pak PH, Maughan WL, Baughman KL, et al. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation. 1998;98:242-248.
91. McDonald K, McWilliams E, O'Keeffe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur Heart J. 1988;9:893-898.
92. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol. 1999;83:903-907.
93. Slade AK, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75:44-49.
94. Tse HF, Yu C, Wong KK, et al. Functional abnormalities in patients with permanent right ventricular pacing: the effect of sites of electrical stimulation. J Am Coll Cardiol. 2002;40:1451-1458.
95. Ommen SR, Nishimura RA, Squires RW, et al. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertropic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol. 1999;34:191-196.
96. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211-214.
97. Knight C, Kurbaan AS, Seggewiss H, et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation. 1997;95:2075-2081.
98. Lakkis NM, Nagueh SF, Kleiman NS, et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998;98:1750-1755.
99. Seggewiss H, Gleichmann U, Faber L, et al. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998; 31:252-258.
100. Kuhn H, Gietzen FH, Leuner C, et al. Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol. 2000;89(suppl 4):IV41-IV54.
101. Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart 2000;83:326-331.
102. Shamim W, Yousufuddin M, Wang D, et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med. 2002;347:1326-1333.
103. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492-1496.
104. Flores-Ramirez R, Lakkis NM, Middleton KJ, et al. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;37:208-214.
105. Schulz-Menger J, Strohm O, Waigand J, et al. The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. Circulation. 2000;101: 1764-1766.
106. Yoerger DM, Picard MH, Palacios IF, et al. Triphasic response to alcohol septal ablation. J Am Coll Cardiol. 2002;39(5 suppl A):157A.
107. Nagueh SF, Stetson SJ, Lakkis NM, et al. Decreased expression of tumor necrosis factor-alpha and regression of hypertrophy after nonsurgical septal reduction therapy for patients with hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1844-1850.
108. Nagueh SF, Lakkis NM, Middleton KJ, et al. Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 1999;99:344-347.
109. Nagueh SF, Lakkis NM, He ZX, et al. Role of myocardial contrast echocardiography during nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1998;32:225-229.
110. Faber L, Seggewiss H, Ziemssen P, Gleichmann U. Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: detection of threatening myocardial necrosis distant from the septal target area. Catheter Cardiovasc Interv. 1999;47:462-466.
111. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415-2421.
112. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38:1701-1706.
113. Lakkis N, Plana JC, Nagueh S, et al. Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. Am J Cardiol. 2001;88:583-586.
114. Gietzen FH, Leuner CJ, Obergassel L, et al. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy New York Heart Association functional class III or IV and outflow obstruction only under provocable conditions. Circulation. 2002;106:454-459.
115. Gaspar J, Martinez-Rios MA, Vonderwalde C, et al. Pericardium-covered stent for septal myocardial ablation in hypertrophic obstructive cardiomyopathy. Catheter Cardiovasc Interv. 1999;47:73-79.
116. Gietzen FH, Leuner J, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Eur Heart J. 1999;20:1342-1354.
117. Seiler C, Hess OM, Schoenbeck M, et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol. 1991;17:634-642.
118. Fananapazir L, Cannon RO 3rd, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and beta-adrenergic blocker therapy. Circulation. 1992;85:2149-2161.
119. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99:2927-2933.
120. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997;18:1249-1256.
121. Begley D, Mohiddin S, Fananapazir L. Dual chamber pacemaker therapy for mid-cavity obstructive hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 2001;24:1639-1644.
122. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29:435-441.
123. Nishimura RA, Hayes DL, Ilstrup DM, et al. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol. 1996; 27:421-430.